{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:37:10Z","timestamp":1786552630585,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["221046"],"award-info":[{"award-number":["221046"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic corticosteroids (SCS) remain the cornerstone of eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) therapy but are associated with substantial toxicity. Mepolizumab, an anti-interleukin-5 biologic, has demonstrated steroid-sparing effects in addition to EGPA and HES disease control, yet evidence of reductions in SCS-related complications is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used US claims data from the Komodo Research Database to quantify SCS-related complications, healthcare resource utilization, and costs in patients with EGPA or HES treated with mepolizumab vs. chronic SCS. Patients were stratified as mepolizumab (300\u2005mg) or chronic SCS users (\u22656 months continuous SCS use with &amp;gt;7.5\u2005mg\/day for EGPA and &amp;gt;10\u2005mg\/day for HES) based on treatment received during a 6-month landmark period post-index (first claim of mepolizumab or SCS). An inverse probability of treatment weighting approach was applied to the cohorts to minimize confounding. Outcomes were assessed up to 12 months post-landmark.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      578 patients with EGPA (305 mepolizumab users vs. 273 chronic SCS users) and 272 patients with HES (161 vs. 111) were included. In patients with EGPA, rates of any SCS-related complications were 39% lower with mepolizumab compared with chronic SCS (rate ratio [95% confidence interval]: 0.61 [0.49, 0.76],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Mepolizumab users had 57% lower rate of all-cause hospitalizations (0.43 [0.27, 0.69],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), and lower outpatient and emergency department (ED) visits vs. chronic SCS. Patients with HES had significantly lower rates of any SCS-related complications with mepolizumab vs. chronic SCS (0.59 [0.42, 0.82],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Mepolizumab users had 66% lower rates of all-cause hospitalizations (0.34 [0.17, 0.65],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), and lower outpatient visits relative to chronic SCS users. In EGPA and HES SCS-complication-related hospitalizations and ED visits were lower with mepolizumab compared with chronic SCS. SCS-complication-related medical costs per patient per year were $16,194 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008) and $3,976 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.676) lower, in the mepolizumab vs. chronic SCS cohort of patients with EGPA and HES, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This first of its kind study suggests that real-world mepolizumab use is associated with reduced SCS-related complications in EGPA and HES, reinforcing its clinical and economic steroid-sparing benefits in reducing healthcare burden among EGPA and HES populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1843149","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:44:12Z","timestamp":1786549452000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study"],"prefix":"10.3389","volume":"7","author":[{"given":"Thanai","family":"Pongdee","sequence":"first","affiliation":[{"name":"Division of Allergic Diseases, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[{"name":"Clinical Development, Amgen","place":["Thousand Oaks, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijita","family":"Deb","sequence":"additional","affiliation":[{"name":"US Real-World Evidence and Health Outcomes Research, Respiratory, GSK","place":["Collegeville, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Laliberte","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Gao","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalise","family":"Hilts","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Liu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy G.","family":"Edgecomb","sequence":"additional","affiliation":[{"name":"US Real-World Evidence and Health Outcomes Research, Anti-infectives and Respiratory, GSK","place":["Collegeville, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.mayocp.2023.02.013","article-title":"Hes and egpa: two sides of the same coin","volume":"98","author":"Khoury","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.anai.2023.02.022","article-title":"Hypereosinophilic syndrome in Europe: retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization","volume":"130","author":"Hwee","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1007\/s10067-021-05783-8","article-title":"Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis","volume":"40","author":"Jakes","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100501","DOI":"10.1016\/j.jacig.2025.100501","article-title":"Burden of hypereosinophilic syndromes in the United States: patients\u2019 perspective","volume":"4","author":"Silver","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B7","doi-asserted-by":"publisher","first-page":"00912-2023","DOI":"10.1183\/23120541.00912-2023","article-title":"Burden of eosinophilic granulomatosis with polyangiitis in Europe","volume":"10","author":"Jakes","year":"2024","journal-title":"ERJ Open Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-Based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British society for rheumatology management recommendations for anca-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"Eular recommendations for the management of anca-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1310211","DOI":"10.3389\/fimmu.2023.1310211","article-title":"Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases","volume":"14","author":"del Pozo","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World health organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am. J. Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.3390\/jcm14124309","article-title":"High disease burden and oral corticosteroid use in patients with hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis: country-level insights into real-world management in Europe","volume":"14","author":"Hwee","year":"2025","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.18553\/jmcp.2016.22.7.833","article-title":"Dose-Response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its Side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-Term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin. Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e003956","DOI":"10.1136\/rmdopen-2023-003956","article-title":"Prospective study of complications and sequelae of glucocorticoid therapy in anca-associated vasculitis","volume":"10","author":"Scherbacher","year":"2024","journal-title":"RMD Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/cells13141180","article-title":"Managing patients with hypereosinophilic syndrome: a statement from the Italian society of allergy, asthma, and clinical immunology (siaaic)","volume":"13","author":"Caminati","year":"2024","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13023-023-02696-4","article-title":"French Guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes","volume":"18","author":"Groh","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase iii, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B24","year":""},{"key":"B25","year":""},{"key":"B26","year":""},{"key":"B27","doi-asserted-by":"publisher","first-page":"00509-2023","DOI":"10.1183\/23120541.00509-2023","article-title":"Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline egpa characteristics","volume":"10","author":"Jayne","year":"2024","journal-title":"ERJ Open Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.anai.2024.11.004","article-title":"Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States","volume":"134","author":"Mathur","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/art.43146","article-title":"Long-term safety and efficacy of mepolizumab in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Wechsler","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/mr\/roae100","article-title":"Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: long-term observation of the Mars study","volume":"35","author":"Ishii","year":"2025","journal-title":"Mod Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.anai.2024.08.272","article-title":"Corticosteroid-Sparing\/End-Organ manifestation benefits observed in real-world patients with hypereosinophilic syndrome\/eosinophilic granulomatosis with polyangiitis receiving mepolizumab","volume":"133","author":"Kovalszki","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clinthera.2013.03.001","article-title":"Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus","volume":"35","author":"Shah","year":"2013","journal-title":"Clin Ther"},{"key":"B35","article-title":"\u201cCorticosteroid Adverse Effects. [Updated 2023 Jul 3]\u201d","volume-title":"StatPearls [Internet]","author":"Yasir","year":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/pds.1673","article-title":"Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score","volume":"17","author":"Austin","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13223-024-00882-y","article-title":"Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma","volume":"20","author":"Casale","year":"2024","journal-title":"Allergy Asthma Clin Immol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European vasculitis study group trials","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ero.2025.10.006","article-title":"Patient perspectives on glucocorticoid-associated complications and sequelae in anca-associated vasculitis","volume":"1","author":"Scherbacher","year":"2025","journal-title":"EULAR Rheumatology Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.anai.2024.08.175","article-title":"Mepolizumab reduces the risk of systemic corticosteroid (SCS)-related complications compared with chronic scs use","volume":"133","author":"Silver","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e70096","DOI":"10.1002\/acr2.70096","article-title":"Discontinuation of oral glucocorticoids and achievement of remission in patients with eosinophilic granulomatosis with polyangiitis treated with benralizumab or mepolizumab","volume":"7","author":"Wechsler","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.18553\/jmcp.2021.21002","article-title":"Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States","volume":"27","author":"Bell","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e42241","DOI":"10.7759\/cureus.42241","article-title":"Retrospective analysis of the burden of illness of eosinophilic granulomatosis with polyangiitis (EGPA) versus asthma in commercially insured US patients","volume":"15","author":"Bell","year":"2023","journal-title":"Cureus"},{"key":"B45","doi-asserted-by":"publisher","first-page":"23743735221143953","DOI":"10.1177\/23743735221143953","article-title":"Insights from social Media on the patient experience of living with rare eosinophil-driven diseases","volume":"9","author":"Strobel","year":"2022","journal-title":"J Patient Exp"},{"key":"B46","first-page":"40","article-title":"Employment, work disability and quality of life in patients with anca-associated vasculitides. The expovas study","author":"Benarous","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1035250","DOI":"10.3389\/fmed.2023.1035250","article-title":"Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome","volume":"10","author":"Roufosse","year":"2023","journal-title":"Front Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ero.2025.08.009","article-title":"Patients\u2019 perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial","volume":"1","author":"Merkel","year":"2025","journal-title":"EULAR Rheumatology Open"},{"key":"B49","doi-asserted-by":"publisher","first-page":"106584","DOI":"10.1016\/j.ejim.2025.106584","article-title":"Mepolizumab improves health-related quality of life in patients with hypereosinophilic syndrome","volume":"145","author":"Roufosse","year":"2026","journal-title":"Eur J Intern Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1136\/annrheumdis-2019-eular.876","article-title":"AB1310 Prospective use of the glucocorticoid toxicity index (GTI) in a cohort of vasculitis patients","volume":"78","author":"Ehlers","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1843149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:44:13Z","timestamp":1786549453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1843149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":51,"alternative-id":["10.3389\/falgy.2026.1843149"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1843149","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1843149"}}